期刊文献+

Protective Effect of Irbesartan by Inhibiting ANGPTL2 Expression in Diabetic Kidney Disease 被引量:2

下载PDF
导出
摘要 Angiopoietin-like protein 2(ANGPTL2)stimulates inflammation and is important in the pathogenesis of diabetic kidney disease(DKD).Irbesartan is helpful in reducing diabetes-induced renal damage.In this study,the effects of irbesartan on DKD and its renal protective role involving ANGPTL2 in DKD rats were examined.Wistar rats were divided into normal,DKD,and DKD+irbesartan groups.The DKD+irbesartan group was treated once daily for 8 weeks with 50 mg/kg irbesartan via intragastric gavage.The 24-h urinary albumin was determined each week,renal pathological changes were observed,and expression of ANGPTL2 and nuclear factor-kappa B(NF-κB)in rat renal tissue was assessed by immunohistochemistry.Mouse podocytes cultured in a high concentration of glucose were classified into four groups based on the irbesartan concentrations(0,25,50,and 75ºg/mL).Expression of ANGPTL2 and phosphorylated IκB-αwas assessed by Western blotting.The mRNA levels of ANGPTL2 and monocyte chemotactic protein 1(MCP-1)were assessed by real-time polymerase chain reaction.The DKD rats displayed proteinuria,podocyte injury,and increased ANGPTL2 and NF-κB expression.All were relieved by irbesartan treatment.In podocytes cultured in elevated glucose,ANGPTL2 and phosphorylated IκB-αwere overexpressed at the protein level,and ANGPTL2 and MCP-1 were highly expressed at the mRNA level.Irbesartan down-regulated ANGPTL2 and phosphorylated IκB-αexpression at the protein level and inhibited ANGPTL2 and MCP-1 expression at the mRNA level.The ameliorative effects of irbesartan against DKD involves podocyte protection and suppression of ANGPTL2.
出处 《Current Medical Science》 SCIE CAS 2020年第6期1114-1120,共7页 当代医学科学(英文)
基金 This study was supported by Jiangsu University Medical Clinical Science and Technology Development(No.JLY201220045).
  • 相关文献

参考文献2

二级参考文献155

  • 1吴义超,刘志红,曾彩虹,苏健,陈朝红,黎磊石.糖尿病肾病患者肾小球基因表达谱及其与病情进展的关系[J].肾脏病与透析肾移植杂志,2004,13(6):503-511. 被引量:14
  • 2陈建康,邹万忠,由江峰.内皮素与肾小球系膜细胞的关系[J].中华病理学杂志,1996,25(4):206-208. 被引量:26
  • 3Locatelli F, Canaud B, Eckardt KU, et al. The importance of diabetic nephropathy in current nephro|ogical practice[J]. Nephrol Dial Transplant,2003, 18 ( 9 ) : 1716-1725. 被引量:1
  • 4Tremolada G, Lattanzio R, Mazzolari G, et al. The therapeutic potential of VEGF inhibition in diabetic microvascular complications[J]. Am J Cardiovasc Drugs, 2007, 7(6) :393-395. 被引量:1
  • 5Ferrara N. Role of vascular endothelial growth factor in the regulation of angiogenesis [J]. Kidney Int, 1999,56 ( 3 ) : 794- 814. 被引量:1
  • 6Suri C, Jones PF, Patan S, et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis [J]. Cell,1996, 87:1171-1180. 被引量:1
  • 7Satchell SC, Mathieson PW. Angiopoietins: microvascular modulators with potential roles in glomerular pathophysiology [ J ]. J Nephrol,2003, 16: 168-178. 被引量:1
  • 8Yamamoto Y, Maeshima Y, Kitayarna H, et al. Tumstatin peptide, an inhibitor of angiogenesis, prevents glomerular hypertrophy in the early stage of diabetic nephropathy [ J ]. Diabetes, 2004, 53: 1831-1840. 被引量:1
  • 9Oike Y, Yasunaga K, Ito Y, et al. Angiopoietin-related growth factor (AGF) promotes epidermal proliferation, remodeling, and regeneration[J].Proc Natl Acad Sci USA, 2003, 100( 16): 9494-9499. 被引量:1
  • 10Ito Y, Oike Y, Yasunaga K, et al. Inhibition of angiogenesis and vascular leakiness by angiopoietin-related protein 4 [J]. Cancer Res, 2003, 63 (20) : 6651 -6657. 被引量:1

共引文献60

同被引文献7

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部